269 essential for clean up after cell death, removal of DNA from blood plasma, and destroying "foreign" DNA from bacteria and viruses consumed by cells (Buzder et al., 2009 ). These roles of cytotoxic endonucleases are less relevant to prostate cancer and thus will not be considered in this review. Although all cells and tissues seem to express all endonucleases, the spectrum of them differs between the tissues. The reason for such redundancy of the cytotoxic endonucleases is not known, which allows speculation about the importance of DNA destruction from immediately prior to long after cell death. The most expressed and active endonuclease in normal prostate is DNase I, previously also known as Ca/Mg-dependent endonuclease . Ca/Mg-dependent endonuclease-mediated DNA fragmentation is used as a marker of apoptosis in prostate cancer. The degradation of genomic DNA into nucleosome-sized fragments is an early event in castration-induced androgen withdrawal that involves death of the androgen-dependent epithelial cells following an increase of endonuclease activity (Banerjee et al., 2000; Brandstrom et al., 1994; . DNase I is found in all studied species and tissues (Lacks, 1981) . It is expressed mainly in tissues of the digestive system, though the specific activity of the enzyme varies between the organs (Gonzalez et al., 2001; Jacob et al., 2002; Lacks, 1981) . In digestive tissues (intestine, pancreas, salivary glands), it is a secreted enzyme intended to hydrolyze DNA in the alimentary tract. In non-digestive tissues (including prostate), the role of DNase I is not known. Bovine or mouse DNase I bind specifically to G-actin and blocks its polymerization (Lacks, 1981) . The enzyme from all sources endonucleolytically cleaves double-or single-stranded DNA to 3'OH/5'P-end oligonucleotides, requires divalent cations, particularly Ca 2+ and Mg 2+ , is inhibited by Zn 2+ , and has a neutral pH optimum. Inside the cell, the enzyme is located in the cytoplasm . It has also been shown inside nuclei, but the mechanism of its introduction into nuclei has not been studied. Inhibition of DNase I by internalized nuclear anti-DNA antibodies was shown to provide protection of cells against apoptotic stimuli (Madaio et al., 1996) . No known nuclear localization signal was identified in DNase I, and "leakage" through nuclear pores was suggested . Among various organs and tissues, prostate, pancreas, salivatory glands and kidney tubular epithelium have the highest levels of DNase I activity (Lacks, 1981; Polzar et al., 1993) . Little is known about DNase I regulation in vivo. An alternative pre-mRNA splicing both in 5'UTR and in coding region was shown to be a mechanism of DNase I regulation (Basnakian et al., 1998; Basnakian et al., 2002) . It is known that some DNase I isoforms can be generated by post-translational modification, namely mannose-type glycosylation of the protein (Lacks, 1981) . Studies of endonucleases associated with prostate cancer are very limited. Usually neoplastic transformation is associated with the decrease of endonuclease expression and activity in various cancers, thus making them "immortal" (Banfalvi et al., 2007; Basnakian et al., 1991; Wang et al., 2008) . The most profound decrease of endonuclease activity was observed in malignant invasive prostate and breast cancer cells Wang et al., 2008) . The decrease of endonuclease activity had been also observed in other cancers and models of carcinogenesis (Basnak'ian et al., 1989; Basnakian et al., 1991) . Immortalization of rat fibroblasts with the S1A segment of SA7 adenovirus also led to a significant decrease of endonuclease activity (Basnak'ian et al., 1989) . Another report indicated that an endonuclease activity is decreased in diethylnitrosamine (DEN)-induced hepatomas i n r a t s c o m p a r e d t o n o r m a l l i v e r t i s s u e (Basnakian et al., 1991) . The decrease was proportional to the degree of dedifferentiation and the activity was the lowest in poorly differentiated tumors. With the decrease of main prostate endonuclease, DNase I, the endonuclease activity in human prostate cancer cells is provided by EndoG. This endonuclease has a unique siteselectivity, initially attacking poly(dG).poly(dC) sequences in double-stranded DNA, as denoted by this enzyme's name. The enzyme also has RNase activity. EndoG predominantly resides in the intermembrane space of mitochondrion (Ohsato et al., 2002) . Mammalian EndoG is synthesized as a 32 kDa propeptide in the cytoplasm and imported into mitochondria through a process mediated by its amino-terminal mitochondriontargeting sequence (Cote & Ruiz-Carrillo, 1993; Ruiz-Carrillo & Renaud, 1987) . The EndoG protein precursor is inactive (Ikeda & Kawasaki, 2001) . The signal peptide is cleaved off after entering the mitochondria and the mature active 27 kDa EndoG is released from mitochondria during apoptosis, moves to the nuclei and cleaves nuclear DNA without sequence specificity . EndoG expression varies in different tissues and in embryonic tissues the expression of EndoG is very low (Apostolov et al., 2007b) . As opposed to DNase I, the enzyme has a greater activity on single-stranded nucleic acid substrates, single-stranded DNA and RNA. It preferentially cleaves non-canonical structures of DNA, damaged DNA, triplex DNA, and R-loops that appear non-specifically during transcription (Masse & Drolet, 1999) . Cisplatin-treated DNA was shown to be preferentially cleaved by EndoG (Ikeda & Ozaki, 1997) . EndoG requires either Mn 2+ or Mg 2+ ions, and is inhibited 15-fold at physiological ionic strengths (Widlak et al., 2001) . Fe 2+ and Zn 2+ inhibit the enzyme activity. The EndoG gene in mice is a single copy gene, which consists of 3 exons (Prats et al., 1997) . The loss of EndoG activity in C.elegans resulted in increased cell survival (Hengartner, 2001) . However, EndoG knockout mouse is viable (Irvine et al., 2005) . Reduction of EndoG in C.elegans using siRNA or genetic mutation affected normal DNA degradation, as revealed by staining with TUNEL assay, and resulted in the delayed appearance of cell corpses during development in C.elegans (Parrish et al., 2001) . Thus in comparison to other endonucleases, EndoG is uniquely compartmentalized in mitochondria and it does not have known intracellular inhibitors (like DNase I or CAD). The EndoG location site may indicate that this enzyme is not an instrument of immediate response to cell injury. EndoG seems to be particularly important in cancer cells because it regulates their sensitivity to chemotherapeutic agents . This report suggests the presence of EndoG in non-invasive breast cancer cells determines their sensitivity to apoptosis, which may be taken into consideration for developing the chemotherapeutic strategy for cancer treatment. In other cells, EndoG has been recognized as a key endonuclease in the caspase-independent apoptosis (Abbott et al., 2001; Bahi et al., 2006) , mitotic catastrophe (Diener et al., ; Wang et al., 2008) , and necrosis (Apostolov et al., 2007a; Jiang et al., 2006) . Because anticancer drugs induce apoptosis in cancer cells through endonuclease-mediated DNA fragmentation (Ploski & Aplan, 2001; Shrivastava et al., 2000) , and the inhibition of endonucleases has a protective effect (Shrivastava et al., 2000) , endonuclease should be considered as important mediators of cancer cell death and potential therapeutic targets for the anticancer therapy. However, delivery of endonucleases or modulation of endonuclease activity are not currently used for cancer therapy, in particular, for prostate cancer therapy.
Modulation of EndoG by DNA methylation and histone deacetylation
Epigenetic changes are believed to be the most common alteration at the DNA level in prostate cancer (Schulz & Hatina, 2006; Walton et al., 2008) . Two types of DNA epigenetic changes that are known to occur in prostate cancer include regional DNA hypermethylation and regional/global DNA hypomethylation. Hypermethylation of the promoter region that contains CpG island occurs in a large number of genes and is usually associated with gene silencing in the vast majority of prostate cancer cases (Li et al., 2005; Perry et al., 2006; Rennie & Nelson, 1998) . Studies have shown that hypermethylation of this region may be eventually used as a tumor biomarker for early diagnosis and risk assessment of prostate cancer. Furthermore, the prevalence of epigenetic changes in prostate cancer and the potential reversibility of DNA methylation alterations by DNA methylation inhibitors suggest that these changes are a viable target for cancer chemotherapy and chemoprevention strategies (Egger et al., 2004; Kopelovich et al., 2003; Yoo & Jones, 2006) . Mammalian genome contains patterns of methylated cytosines for normal function, but until recently the structural organization of the methylation landscape of the human genome was unclear (Rollins et al., 2006) . It has been reported that the human genome consists of short (<4 kb) unmethylated domains enriched in promoters, CpG islands, and first exons, embedded in a matrix of long methylated domains (Rollins et al., 2006) . Analysis of promoter sequences of all known human cytotoxic endonucleases -described belowshowed that EndoG is the only cytotoxic endonuclease that contains a CpG island, a segment of DNA with high G+C content and a site for methylation, in the promoter region (Wang et al., 2008) . A large number of studies have shown that methylation of promoter CpG islands plays an important role in gene silencing (Ruchusatsawat et al., 2006; Taghavi & van Lohuizen, 2006) . The broadly accepted definition of a CpG island as a 200-bp fragment of DNA with G + C content greater than 50% and observed CpG/expected CpG ratio higher than 0.6 failed to exclude many sequences (such as Alu repeats and unknown sequences) that are not associated with regulatory regions of genes (Takai & Jones, 2002) . Recent studies indicate that the usage of a modified algorithm to search for CpG islands using a more stringent definition (G + C content higher than 55% and a length greater than 500 bp with observed CpG/expected CpG ratio 0.65) resulted in the exclusion of the majority of Alu repetitive and unknown sequences associated with the 5' region of genes (Takai & Jones, 2002) . In view of these considerations, we applied this algorithm to the analysis of endonuclease genes, which could be regulated by DNA methylation. All known human cell death endonucleases and their sequence variants were analyzed using the CpG Island Searcher program (available at http://www.cpgislands.com (Takai & Jones, 2003) ): DNase 1, DNase 1L1 variants 1, 2, 3 and 4; DNase 1L2, DNase 1L3 (DNase gamma), DNase 2 , DNase 2 variants 1 and 2, L-DNase II (LEI), CAD and EndoG. Surprisingly, this analysis showed that EndoG is the only gene that satisfied the criteria of containing a long CpG island in the promoter and exon 1 of the gene.
The methylation status of the EndoG promoter/exon 1 in prostate cancer cells was then determined by using the methylation-sensitive McrBC-PCR method. McrBC is a bacterial endonuclease, that does not act on unmethylated DNA, but cleaves DNA containing 5methylcytosine in one or both strands and thus nullifies PCR amplification (Nakayama et al., 2004) . This experiment showed that in three studied prostate cancer cell lines, LNCaP, 22Rv1 and PC3, EndoG promoter methylation was the lowest in 22Rv1 cells and highest in PC3 cells. Further comparison of the three prostate cancer cell lines showed that EndoG is highly expressed in 22Rv1 and LNCaP cells. In PC3 cells, EndoG was not expressed and the EndoG gene CpG island was hypermethylated (Wang et al., 2008) . The expression of EndoG correlated positively with sensitivity to docetaxel, cisplatin and etoposide, and the silencing of EndoG by siRNA decreased the sensitivity of the cells to the chemotherapeutic agents in the two EndoG-expressing cell lines. To determine whether the level of EndoG expression affects the sensitivity of prostate cancer cells to chemotherapeutic drugs, we exposed the three cell lines to two anticancer agents, cisplatin (0-100 µM) and etoposide (0-300 µM), which are known to induce cell death in vitro (Fang et al., 2004; Lee et al., 2006) . As expected, the two cell lines that expressed EndoG, 22Rv1 and LNCaP, were highly sensitive to both chemotherapeutic agents. EndoG-deficient PC3 cells, in contrast, were insensitive to these drugs in the range of concentrations used. Further study determined that cisplatin-induced death of prostate cancer cells can be prevented by EndoG silencing. Although EndoG is known to participate in cell death, it was necessary to determine whether the role of EndoG was the same in prostate cancer cells subjected to injury by cytotoxic agents as has been described in other cells. To test a causal relationship, EndoG was silenced in 22Rv1 cells by applying siRNA. To show that siRNA was delivered to the cells, fluorescent DY547-labeled siRNA was used. After DY547-siRNA transfection, 22Rv1 cells were exposed to 80 μM cisplatin, a concentration that had induced significant cell death in the above experiments. Next, TUNEL assay was conducted to measure DNA fragmentation. The assay showed the DNA fragmentation was decreased, indicating that silencing of EndoG leads to significant decrease of EndoG expression and protects cells from DNA fragmentation. As expected, EndoG silencing resulted in the increased viability of cisplatin-treated 22Rv1 cells as measured using clonogenic assay. The results suggest EndoG is responsible for cisplatin-induced death in prostate cancer cells. It is interesting that inhibition of DNA methylation induced EndoG and increased sensitivity of PC3 cells to cisplatin and etoposide. 5-aza-2'-deoxycytidine (decitabine), which is a DNA methylation inhibitor, caused hypomethylation of the EndoG promoter in PC3 cells, induced EndoG mRNA and protein expression, and made the cells sensitive to the chemotherapy agents. Using McrBC-PCR method, we determined that the treatment of PC3 cells with decitabine inhibited methylation of the CpG island in the EndoG gene. The same concentration of decitabine also increased EndoG expression as determined by real-time RT-PCR and Western blotting. These data clearly suggested EndoG expression is regulated by DNA methylation. Importantly, the induction of EndoG by demethylation caused a significant increase in sensitivity to cisplatin and etoposide. Finally, the acetylation of histones by trichostatin A (TSA), a histone deacetylase inhibitor, induced EndoG expression in 22Rv1 cells, while it had no such effect in PC3 cells. These data indicated EndoG may be regulated by methylation of its gene promoter, and partially by histone acetylation, and that EndoG is essential for prostate cancer cell death in the used models. Histone modification, in particular, histone acetylation, is another epigenetic mechanism that is important in regulation of genes in prostate cancer Egger et al., 2004; Wang et al., 2008; Yoo & Jones, 2006) . To determine whether and how histone acetylation regulates EndoG expression, two prostate cancer cell lines were treated with TSA, and EndoG protein expression was studied using Western blotting. The exposure of the cells to TSA induced high levels of EndoG expression in EndoG-positive 22Rv1 cells, whereas in EndoG-deficient PC3 cells, EndoG was not induced. Again, EndoG induction by TSA caused increased sensitivity to cisplatin. These data demonstrated that chromatin acetylation is important for EndoG expression. Taken together with the above methylation experiments, these data indicate that DNA methylation plays a primary role in EndoG regulation as compared to histone acetylation. In other words, the CpG island of the EndoG gene has to be hypomethylated in order to allow regulation of EndoG expression by histone acetylation.
Endonuclease delivery to prostate cancer cells and tumors
Although these are attractive and potentially therapeutically useful approaches, modulations of endonuclease expression by DNA methylation or histone acetylation may not be a realistic approach because the specificity of epigenetic regulation is notoriously low. An alternative to these methods may be a gene delivery and overexpression in the target cancer cells. To determine whether overexpression of EndoG would make PC3 cells sensitive to the chemotherapy agents, the cells were transfected with human mature EndoG gene. To model chemotherapy in vitro, we used docetaxel, which is an FDAapproved the first line chemotherapeutic agent in castration-refractory prostate cancer (Oudard et al., 2007; Ryan et al., 2001) . Despite survival benefits with docetaxel based chemotherapy, prognosis for castration-refractory prostate cancer patients usually is poor and patients typically show rapid progression (Oudard et al., 2005; Wang et al., 2008) . Progressive prostate cancer is associated with the development, and subsequent expansion of tumor cells that are resistant to apoptotic triggers and dysregulation of apoptosis is often characterized by insufficient apoptosis (Kruslin, 2009; Mori et al., 1996) . Therefore a delivery of EndoG gene was expected to increase sensitivity of prostate cancer cells to docetaxel. As described below, this genetic manipulation resulted in significant increase of PC3 cells sensitivity to docetaxel and cisplatin in vitro. Similar results were obtained when PC3 cells were transfected with EndoG precursor gene suggesting that the drugs induce speedy processing of the protein to mature endonuclease. PC3 cells were chosen because they have very low expression of EndoG (Wang et al., 2008) . Human EndoG gene (NM 004435.2) was cloned in the mammalian expression vector pECFP.N1 to result in an expression of EndoG protein fused with the enhanced cyan fluorescence protein (CFP). The expression of the chimeric protein was confirmed by fluorescent microscopy. Cells were then treated with docetaxel and cell death was measured using lactate dehydrogenase (LDH) release assay. This experiment showed the sensitivity of the PC3 cells expressing EndoG-CFP to docetaxel was much higher than the cells expressing CFP alone (Figure 1) . The same result was also observed in cisplatin-induced cells death:
EndoG overexpression resulted in an over 4-folds elevation of cisplatin-induced cell death (data not shown). We also have compared mature EndoG gene and precursor EndoG gene overexpression cytotoxicity and their effects on cisplatin-induced cell death, and found that both types of EndoG had familiar effect (data not shown). Fig. 1 . EndoG expression enhances prostate cancer cells' sensitivity to docetaxel in vitro. Left panel: Cell death measured by LDH release assay in EndoG-expressing 22Rv1 and EndoGnegative PC3 cells, which were exposed to varying concentrations of docetaxel for 24h (n=4, *p<0.05). Right panel: Cell death measured by LDH release assay in PC3 cells with or without EndoG precursor overexpression 24 hrs after exposure to varying concentrations of docetaxel (n=4, *p<0.05).
Finally, parental PC3 cells and PC3 cells overexpressing human EndoG precursor were implanted in prostates of SCID mice to produce orthotopic tumors. The animals with xenografts were subjected to the docetaxel chemotherapy and the tumor size progression was monitored by high frequency ultrasound visualization. This experiment showed that EndoG-expressing tumors shrink in response to chemotherapy, while control tumors made of EndoG-negative parental PC3 cells were chemoresistant. To produce orthotopic xenografts, 8-weeks old male SCID mice were injected with human prostate cancer PC3 cells or EndoG gene-transfected PC3 cells by surgical orthotopic implantation. 2x10 5 cells were mixed with matrigel at 1:1 ratio (v/v) in a total volume of 20μl were injected in the left ventral prostate lobes after surgical opening of the lower abdomen skin and peritoneal membrane. Ultrasound image could identify prostate tumor as early for 6 days after implantation. Monitoring of the tumor growth showed that the prostate lobe eventually was occupied by the tumor and lost its original shape. At the 12 th day, the mice received docetaxel (10mg/kg) via peritoneal cavity injection while the control mice received saline injection. Ultrasound images were taken at the 6, 12, and 18 days after orthotopic implantation. By day 18, PC3 xenograft tumors significantly grew up regardless of the docetaxel treatment; EndoG-PC3 xenografts without docetaxel treatment grew up less, while the docetaxel-treated EndoG-PC3 xenografts did not grow in size and instead shrunk ( Figure 2 ). Histology analysis confirmed the EndoG overexpression in tumors, which coincided with positive TUNEL staining, thus confirming EndoG overexpression made xenografts sensitive to the docetaxel treatment. Human prostate cancer PC3 cells were transfected with EndoG precursor gene. Parental EndoG-deficient cells or EndoG-expressing PC3 cells were implanted in ventral prostate. Docetaxel (10 mg/kg) was administrated at the 12th day after implantation. Tumor sizes were monitored by intravital ultrasound sonography using VisualSonics Vevo 770 instrument. Arrows indicate tumor edges.
Conclusive remarks
Overall, our studies demonstrated that the expression and activity of the cytotoxic endonucleases are decreased in prostate cancer cells that are resistant to chemotherapy (Wang et al., 2008) . This is consistent with previous studies of breast cancer, which also showed disappearance of DNase I in immortalized breast epithelial cells, and decrease of EndoG that coincided with dedifferentiation and invasiveness of breast cancer . EndoG is shown essential for prostate cancer cell death induced by chemotherapy. Expression of EndoG positively correlated with the sensitivity to chemotherapeutic agents cisplatin and etoposide, while the silencing of EndoG by siRNA in two cancer lines, 22Rv1 and LNCaP, decreased the sensitivity of the cells to the chemotherapeutic agents. In PC3 cell line, which does not express EndoG, the chemotherapeutic agent 5-aza-2'-deoxycytidine caused hypomethylation of the EndoG promoter, induced EndoG expression, and made the cells sensitive to both cisplatin and etoposide. In our latest studies described above, the overexpression of EndoG in PC3 cells made them also sensitive to docetaxel in vitro and in vivo. Therefore these studies demonstrate the first application of endonucleases as a helper drug for the chemotherapy of prostate cancer. Because the mechanisms of chemo-and radiosensitivity of cells are very similar, these observations may be easily extrapolated to the radiotherapy of prostate cancer. Future studies may be necessary to determine the role of other epigenetic mechanisms in regulation of EndoG and their role in chemoresistance to prostate cancer and cancers of other organs. Chemotherapy is currently one of the frequently used therapeutic strategies for prostate cancer (Dyrstad et al., 2006; Kaku et al., 2006; Nakabayashi & Oh, 2006) , and measurement of EndoG may be a potentially useful approach to evaluate chemosensitivity of cancer cells to determine optimal conditions for chemotherapy prior to the therapy. If further in vivo studies confirm our observation that EndoG is a potential key mediator of prostate cancer cell death regulated by the methylation of EndoG gene promoter, future epigenetic therapeutics will need to be targeted to EndoG. A development of this approach may lead to similar therapeutic strategies for cancer of other organs. Recent study determined that DNase I and EndoG, which represent most of DNase activity in prostate epithelial and many other cells and are linked in a single pathway, in which DNase I expression positively modulates EndoG expression (Yin et al., 2007) . DNase I has the highest specific activity (per mg protein) among all known endonucleases, and it is the only endonuclease that can be directly incorporated into cells. The mechanisms of DNA destruction and the role in cell death are same between the two endonucleases. Therefore, it may not be necessary to deliver EndoG gene to prostate tumors and instead deliver DNase I protein packed in liposomes, which are attractive as vehicles because they have low toxicity. The only example of an endonuclease being applied for a therapy is human recombinant DNase I is used in complex therapy of cystic fibrosis. Future studies may lead to the first application of endonucleases as a helper drug for chemotherapy of prostate cancer.
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